Lung Cancer Clinical Trial
Official title:
Ex-Vivo Evaluation of the Effectiveness of Pulmonary Artery Sealing Using the HARMONIC ACE + Shears (HS) for VATS Lobectomy
VATS anatomical lung resection provides an effective minimally invasive treatment strategy
for stage I and II lung cancer. VATS lobectomy is associated with significantly less
postoperative atrial fibrillation, blood transfusion, renal failure, and other complications
when compared with lobectomy via thoracotomy.
Although VATS lobectomy has been proven to be effective and safe in experienced hands, it is
not devoid of risk. Intra-operative surgical complications can be at times catastrophic.
Currently, in spite of being a safe and effective technique in experienced hands, a minority
of anatomical pulmonary resections are being performed by VATS. The technical difficulty and
increased actual and perceived danger of VATS lobectomy is related to PA branch manipulation
and this is the main limitation for many thoracic surgeons regarding the adoption of VATS
lobectomy into their practise. Furthermore, the majority of VATS lobectomies are being
performed in high volume, academic medical centers with a resultant disparity in
socioeconomic status between those that undergo VATS versus open lobectomy. If we can find a
way to decrease the manipulation required by the surgeon on the PA branches, these
procedures will be safer, less stressful for the surgeon and therefore more prevalent for
anatomical pulmonary resections.
The intraoperative techniques will not differ from standard resection techniques and blood
vessel ligation will be performed according to standard operative procedures either using
endostaplers or direct ligation of the pulmonary vessels.
After resection and removal of the resected specimen, the specimen will be examined ex-vivo,
out of the operative field in a non-sterile field in the operative room. The lobar PA and
its main segmental branches will be sharply dissected. Cannulation of a major segmental PA
branch will be performed using our pressurization and monitoring device. The cannulation
will be secured with a 2-0 silk suture. The vascular pressurization and recording device has
been described in section E and is outlined in Figures 4 and 5. All pressure measurements
will be recorded and graphed related to time from initial vascular pressurization to PA
bursting pressure.
All distal segmental branches of the PA will be ligated to maintain the pressure throughout
the catheterized segmental branch. An initial pressure of 25 mmHg will be obtained by
inflating the vessel with normal saline. The lobar PA and the main segmental branches'
diameters will be measured from vascular adventitia to adventitia. The lobar PA and the main
segmental arteries will be sealed using the Harmonic Scalpel Ace+. The sealing will be
performed with an intravascular pressure of 25 mmHg in order to simulate normal human PA
pressures.
Following division of the PA, normal saline solution will be injected through the controlled
pressure syringe pump in order to achieve an intralumenal vascular pressure until the
bursting pressure is reached. Intralumenal pressure will be recorded at a frequency of 10
times per second. The bursting pressure will be recorded. Ex-vivo experimentation will take
approximately 20 to 30 minutes. Burst pressure of the in-vivo endo-stapled (Endopath® ETS,
35mm, 2.5mm staples, white cartridge; Ethicon, Cincinnati, Ohio, USA) main lobar PA branches
will be evaluated and recorded ex-vivo on the same specimens.
Endo-stapled vessels will be utilized as the size-matched control for energy sealed vessels
in a 1:2 ratio. Allotment into the stapled or energy sealed group will be based on vascular
size measurement prior to sealing. Attempts will be made to use the in-vivo staple line as
the control vessel in all possible cases (size permitting) in order to increase the sample
size of the energy sealed vessels.
Following vascular sealing, experimentation and recordings, the specimen will be sent for
pathological evaluation of the resected lesion. All specimen manipulations will be strictly
performed on the proximal main PA branches, away from the resected tumour. Care will be
taken to not affect the pathological integrity of the resected lesion and its surrounding
tissue and lymph nodes. Experimentation will be performed under the direct supervision of
the attending thoracic surgeon in order to assure integrity of the specimen for pathological
analysis.
Analysis will consist of between group comparisons of the efficacies and bursting pressure
of both the energy sealed vessels (experimental group) and the endostapler-sealed vessels
(control group). Vessels will be stratified by luminal diameter by millimeter. Primary
outcome for analysis will be the intergroup comparisons of mean PA burst pressure by size of
vessel. Intergroup differences will be compared with the student's t-test with bursting
pressures entered as a continuous variable. Statistical testing for normality of data will
be performed and when data is non-normal, non-parametric methods (ex: Wilcoxon Rank Sum
Test…) will be used. Multivariable linear regression models will be employed in order to
compare burst pressures between groups controlling for potential confounders (disease state,
size of vessel sealed, age of patient, sex, pulmonary lobe, laterality, immunosupression,
diabetes, vascular disease…).
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|